Literature DB >> 24485213

The effect of hypoglycemia on health-related quality of life: Canadian results from a multinational time trade-off survey.

Stewart Harris1, Muhammad Mamdani2, Claus B Galbo-Jørgensen3, Mette Bøgelund3, Jens Gundgaard4, Danielle Groleau5.   

Abstract

OBJECTIVE: The aim of this study was to investigate the impact of hypoglycemia according to severity and time of onset on health-related quality of life (HRQoL) in a Canadian population.
METHODS: Time trade-off (TTO) methodology was used to estimate health utilities associated with hypoglycemic events in a representative sample of the Canadian population. A global analysis conducted in the United Kingdom, Canada, Germany and Sweden has been published. The present Canadian analysis focuses on 3 populations: general, type 1 and type 2 diabetes. Using a web-based survey, participants (>18 years) assessed the utility of 13 different health states (severe, non-severe, daytime and nocturnal hypoglycemia at different frequencies) using a scale from 1 (perfect health) to 0 (death). The average disutility value for each type of event was calculated.
RESULTS: Of 2258 participants, 1696 completers were included in the analysis. A non-severe nocturnal hypoglycemic event was associated with a significantly greater disutility than a non-severe daytime event (-0.0076 vs. -0.0056, respectively; p=0.05), while there was no statistically significant difference between severe nocturnal and severe daytime events (-0.0616 vs. -0.0592; p=0.76). Severe hypoglycemia was associated with greater disutility than non-severe hypoglycemia (p<0.0001). Similar trends were reported in participants with diabetes.
CONCLUSIONS: The findings presented here show that any form of hypoglycemia had a negative impact on HRQoL in a Canadian population. Nocturnal and/or severe hypoglycemia had a greater negative impact on HRQoL compared with daytime and/or non-severe events. This highlights the importance of preventing the development and nocturnal manifestation of hypoglycemia in patients with diabetes.
Copyright © 2014 Canadian Diabetes Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Canada; diabetes mellitus; diabète sucré; hypoglycemia; hypoglycémie; quality of life; qualité de vie; théorie de l’utilité; utility theory

Mesh:

Year:  2014        PMID: 24485213     DOI: 10.1016/j.jcjd.2013.09.001

Source DB:  PubMed          Journal:  Can J Diabetes        ISSN: 1499-2671            Impact factor:   4.190


  23 in total

1.  Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial.

Authors:  Wen Wan; M Reza Skandari; Alexa Minc; Aviva G Nathan; Parmida Zarei; Aaron N Winn; Michael O'Grady; Elbert S Huang
Journal:  Med Decis Making       Date:  2018-11       Impact factor: 2.583

2.  Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial.

Authors:  Wen Wan; M Reza Skandari; Alexa Minc; Aviva G Nathan; Aaron Winn; Parmida Zarei; Michael O'Grady; Elbert S Huang
Journal:  Diabetes Care       Date:  2018-04-12       Impact factor: 19.112

3.  Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis.

Authors:  Neda Laiteerapong; Jennifer M Cooper; M Reza Skandari; Philip M Clarke; Aaron N Winn; Rochelle N Naylor; Elbert S Huang
Journal:  Ann Intern Med       Date:  2017-12-12       Impact factor: 25.391

4.  Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA.

Authors:  Tadesse M Abegaz; Vakaramoko Diaby; Fatimah Sherbeny; Askal Ayalew Ali
Journal:  Clin Drug Investig       Date:  2022-05-25       Impact factor: 2.859

5.  Factors associated with nocturnal hypoglycemia in at-risk adolescents and young adults with type 1 diabetes.

Authors:  Darrell M Wilson; Peter M Calhoun; David M Maahs; H Peter Chase; Laurel Messer; Bruce A Buckingham; Tandy Aye; Paula K Clinton; Irene Hramiak; Craig Kollman; Roy W Beck
Journal:  Diabetes Technol Ther       Date:  2015-03-11       Impact factor: 6.118

6.  Estimating the utility value of hypoglycaemia according to severity and frequency using the visual analogue scale (VAS) and time trade-off (TTO) survey.

Authors:  Asrul Akmal Shafie; Chin Hui Ng; Subramaniam Thanimalai; Norliza Haron; Anita Bhajan Manocha
Journal:  J Diabetes Metab Disord       Date:  2018-11-07

7.  Pharmacogenetic-guided glimepiride therapy in type-2 diabetes mellitus: a cost-effectiveness study.

Authors:  Cécile Fokoun; Hassan Serrier; Hugo Rabier; Sylvain Goutelle; Michel Tod; Laurent Bourguignon
Journal:  Pharmacogenomics J       Date:  2021-03-17       Impact factor: 3.550

8.  Effects of continuous glucose monitor-recorded nocturnal hypoglycaemia on quality of life and mood during daily life in type 1 diabetes.

Authors:  Marie M Henriksen; Henrik U Andersen; Birger Thorsteinsson; Ulrik Pedersen-Bjergaard
Journal:  Diabetologia       Date:  2021-01-14       Impact factor: 10.122

9.  Modern insulins, old paradigms and pragmatism: choosing wisely when deciding how to treat type 1 diabetes.

Authors:  Beatriz D Schaan; Rafael Selbach Scheffel
Journal:  Diabetol Metab Syndr       Date:  2015-04-22       Impact factor: 3.320

Review 10.  Evaluating health-related quality of life in type 1 diabetes: a systematic literature review of utilities for adults with type 1 diabetes.

Authors:  Jayne Smith-Palmer; Jay P Bae; Kristina S Boye; Kirsi Norrbacka; Barnaby Hunt; William J Valentine
Journal:  Clinicoecon Outcomes Res       Date:  2016-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.